Directorate Change

Smith & Nephew Plc
06 December 2023


Smith+Nephew announces change in Audit Committee Chair


6 December 2023                 

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that Rick Medlock has notified the Board of his decision not to submit himself for re-election as a Non-Executive Director at the next annual general meeting of the Company.

Jez Maiden, Non-Executive Director, will be appointed Chair of the Audit Committee with effect from 1 March 2024.

The Board would like to thank Rick for his commitment and contribution to the Board and the Company and to congratulate Jez on his new appointment.


Investors / Analysts

Andrew Swift



+44 (0) 1923 477433


Charles Reynolds



+44 (0) 1923 477314

Susan Gilchrist / Ayesha Bharmal

+44 (0) 20 7404 5959



Jez Maiden Biography

Key skills and competencies

Jez joined the Board in 2023 and has extensive financial experience across a diverse range of industries and sectors. Jez was Chief Financial Officer of 5 UK-listed companies over a period of 24 years and has served as a Non-Executive Director on boards of companies addressing strategic and operational challenges across a number of different industries, including life-sciences and healthcare. He was previously Chair of the Audit Committee at Synthomer PLC and PZ Cussons plc.

Current external appointments


Senior Independent Director, Travis Perkins plc. Non-Executive Director and member of the Audit Committee at Intertek Group plc.

Previous experience


Jez retired in 2023 as Group Finance Director at Croda International plc, the FTSE 100 global speciality chemicals company, and previously held similar roles at National Express Group plc and Northern Foods Limited. He has served as the Senior Independent Director at Synthomer PLC and at both PZ Cussons plc and Synthomer PLC he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants.


About Smith+Nephew


Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 19,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.


Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.


For more information about Smith+Nephew, please visit and follow us on XLinkedInInstagram or Facebook.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings